Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 9/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.36 |
| ▸ | CCNC | P24863 | 1/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21177854 | 0.99 | PRKDC (0.41) | PRKDCERBB2SYKIRAK4CCNC | |
| SCHEMBL21178261 | 0.89 | ERBB2 (0.40) | PRKDCERBB2IRAK4KCNH2 | |
| SCHEMBL21187311 | 0.89 | ERBB2 (0.40) | PRKDCERBB2IRAK4KCNH2 | |
| SCHEMBL21178142 | 0.88 | MAPK1 (0.46) | PRKDCERBB2 | |
| SCHEMBL21177861 | 0.88 | LMNA (0.41) | PRKDCERBB2IRAK4 | |
| SCHEMBL30823286 | 0.88 | LMNA (0.41) | PRKDCERBB2IRAK4 | |
| SCHEMBL21187306 | 0.88 | MAPK1 (0.46) | PRKDCERBB2 | |
| SCHEMBL21177841 | 0.88 | LMNA (0.41) | PRKDCERBB2IRAK4 | |
| SCHEMBL21177844 | 0.88 | LMNA (0.41) | PRKDCERBB2IRAK4 | |
| SCHEMBL21179453 | 0.87 | ERBB2 (0.38) | PRKDCERBB2CCNCCDK8KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-11-12 | — | — | US | disclosed |
| WO-2019143678-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200353101-A1 | DNA-PK INHIBITORS | POLK, DTYMK, DCK | PRKDC 34/4885ERBB2 953/4885SYK 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.